Autonomix Medical (AMIX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Sep, 2026Executive summary
Annual Meeting scheduled for October 29, 2026, with proxy materials available online and by request, aiming to reduce environmental impact and costs.
Shareholders of record as of September 8, 2026, are eligible to vote on four key proposals, with a quorum requirement of one-third of voting power.
Voting can be done online, by mail, or in person, with clear procedures for proxy revocation and vote counting.
Voting matters and shareholder proposals
Proposal 1: Election of six directors to serve until the 2027 annual meeting.
Proposal 2: Ratification of Forvis Mazars, LLP as independent auditor for fiscal year ending March 31, 2027.
Proposal 3: Amendment to authorize a reverse stock split at a ratio between 1-for-2 and 1-for-25, at the Board's discretion, within one year.
Proposal 4: Approval of an amendment to the 2023 Equity Incentive Plan to increase shares authorized for issuance.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of six members, with four deemed independent under Nasdaq rules.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, each with independent members and defined charters.
Board and committees held a total of 13 meetings in fiscal 2026, with high attendance.
Policies in place include anti-hedging, insider trading, and a code of ethics.
Latest events from Autonomix Medical
- Key votes include director elections, auditor ratification, reverse split, and equity plan.AMIX
Proxy filing - Board seeks approval for director elections, auditor, reverse split, and expanded equity plan.AMIX
Proxy filing - Registering 1,071,826 shares for resale via warrants, with proceeds for working capital if exercised.AMIX
Registration filing - Precision-guided nerve ablation technology shows strong clinical results and targets a $100B market.AMIX
Investor presentation - Net loss narrowed, cash runway shortens, and new capital raised via warrant inducement amid going concern risks.AMIX
Q1 2027 - Registering 857,462 shares for resale via warrants, with proceeds for working capital and high dilution risk.AMIX
Registration filing - Offering up to 698,812 units to fund clinical trials, with high risk and significant capital needs.AMIX
Registration filing - Medical device firm targets $200M shelf and $2.1M ATM amid high risk and going concern warning.AMIX
Registration filing - Offering up to 698,812 units to fund clinical trials, with no revenue and high ongoing losses.AMIX
Registration filing